How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.


Means and methods for diagnosing and treating inflammatory disorders

Organization name

Clinic Invent



Depending on pattern recognition receptors (PRRs) such as toll like receptors (TLRs), the innate immune system can be activated by pathogen associated molecular patterns (PAMPs) like lipopolysaccharides (LPS) or by damage associated molecular patterns (DAMPs; also termed 'alarmins'). DAMPs are endogenous molecules such as cellular proteins, lipids or nucleic acids. DAMP-functions are well described for the members of the calgranulin protein family, S100A8/A9 and S100A12, which are highly overexpressed in certain autoinflammatory diseases where their non-classical cellular release or spontaneous hypersecretion correlates with disease causing genotype and coincides with local as well as systemic inflammatory activity.


We previously demonstrated human mon-cytes to respond to S100A12 stimulation in an exclusively TLR4-dependent manner and have now found that binding of S100A12 to TLR4 and, in particular, the TLR4-dependent inflammatory stimulation requires the organization of the protein into a hexameric ring structure consisting of six similar building blocks. While current anti-inflammatory therapies target cytokines which can arise downstream of TLR4-activation, our structural understanding of the S100A12-TLR4 interaction now allows to specifically target TLR4-activation by an endogenous molecule as an inherent disease perpetuating phenomenon in autoinflammation.

Advantages of the invention

  • more precise monitoring of inflammatory processes
  • benefit for patients affected by complex genetic autoinflammatory diseases
  • development of low-risk therapeutics

Patent situation

Patent applications filed in Europe and USA.

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.


latest entries